ATE131872T1 - Latenz assoziierte peptide und deren verwendung - Google Patents
Latenz assoziierte peptide und deren verwendungInfo
- Publication number
- ATE131872T1 ATE131872T1 AT90917236T AT90917236T ATE131872T1 AT E131872 T1 ATE131872 T1 AT E131872T1 AT 90917236 T AT90917236 T AT 90917236T AT 90917236 T AT90917236 T AT 90917236T AT E131872 T1 ATE131872 T1 AT E131872T1
- Authority
- AT
- Austria
- Prior art keywords
- beta
- sequence
- tgf
- mature tgf
- latency
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 4
- 101800001155 Latency-associated peptide Proteins 0.000 abstract 2
- 102400000401 Latency-associated peptide Human genes 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 230000002939 deleterious effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229940124644 immune regulator Drugs 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Transplantation (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44168089A | 1989-11-22 | 1989-11-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE131872T1 true ATE131872T1 (de) | 1996-01-15 |
Family
ID=23753857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT90917236T ATE131872T1 (de) | 1989-11-22 | 1990-10-30 | Latenz assoziierte peptide und deren verwendung |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0502036B1 (de) |
| JP (1) | JPH05503003A (de) |
| AT (1) | ATE131872T1 (de) |
| AU (1) | AU639047B2 (de) |
| CA (1) | CA2068204C (de) |
| DE (1) | DE69024369T2 (de) |
| DK (1) | DK0502036T3 (de) |
| ES (1) | ES2083469T3 (de) |
| GR (1) | GR3019343T3 (de) |
| WO (1) | WO1991008291A2 (de) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992000318A1 (en) * | 1990-06-25 | 1992-01-09 | Oncogene Science, Inc. | Tissue-derived tumor growth inhibitors, methods for preparation and uses thereof |
| US6395494B1 (en) | 1993-05-13 | 2002-05-28 | Neorx Corporation | Method to determine TGF-β |
| US7393682B1 (en) | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
| US6607884B1 (en) | 1993-03-19 | 2003-08-19 | The Johns Hopkins University School Of Medicine | Methods of detecting growth differentiation factor-8 |
| US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
| ES2201076T3 (es) | 1993-03-19 | 2004-03-16 | The Johns Hopkins University School Of Medicine | Factor-8 de diferenciacion del crecimiento. |
| US7566768B1 (en) | 1995-10-26 | 2009-07-28 | The Johns Hopkins University School Of Medicine | Promyostatin peptides and methods of using same |
| US7332575B2 (en) | 1994-03-18 | 2008-02-19 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species |
| US5708142A (en) | 1994-05-27 | 1998-01-13 | Genentech, Inc. | Tumor necrosis factor receptor-associated factors |
| ATE242809T1 (de) | 1995-09-08 | 2003-06-15 | Genentech Inc | Vegf-verwandtes protein |
| US6030945A (en) * | 1996-01-09 | 2000-02-29 | Genentech, Inc. | Apo-2 ligand |
| US6998116B1 (en) | 1996-01-09 | 2006-02-14 | Genentech, Inc. | Apo-2 ligand |
| EP0904366A1 (de) | 1996-04-01 | 1999-03-31 | Genentech, Inc. | Apo-2li and apo-3 apoptosis polypeptiden |
| US6159462A (en) * | 1996-08-16 | 2000-12-12 | Genentech, Inc. | Uses of Wnt polypeptides |
| US5851984A (en) * | 1996-08-16 | 1998-12-22 | Genentech, Inc. | Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides |
| US6462176B1 (en) | 1996-09-23 | 2002-10-08 | Genentech, Inc. | Apo-3 polypeptide |
| AU729158B2 (en) | 1997-01-31 | 2001-01-25 | Genentech Inc. | O-fucosyltransferase |
| US6100076A (en) * | 1997-01-31 | 2000-08-08 | Genentech, Inc. | O-fucosyltransferase |
| GB9702943D0 (en) * | 1997-02-13 | 1997-04-02 | Univ Manchester | Wound healing |
| WO1998046588A2 (en) | 1997-04-11 | 1998-10-22 | Neorx Corporation | Compounds and therapies for the prevention of vascular and non-vascular pathologies |
| US6342369B1 (en) | 1997-05-15 | 2002-01-29 | Genentech, Inc. | Apo-2-receptor |
| US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
| ATE411385T1 (de) | 1998-01-15 | 2008-10-15 | Genentech Inc | Apo-2 ligand |
| US7141392B2 (en) | 2001-01-09 | 2006-11-28 | Queen Mary And Westfield College | Latent fusion protein |
| US6942853B2 (en) | 2001-01-09 | 2005-09-13 | Queen Mary And Westfield College | Latent fusion protein |
| KR100844062B1 (ko) | 2001-02-21 | 2008-07-07 | 미쓰이 가가쿠 가부시키가이샤 | 올레핀 중합용 촉매 및 이 촉매를 사용하는 올레핀중합체의 제조방법 |
| US6613083B2 (en) | 2001-05-02 | 2003-09-02 | Eckhard Alt | Stent device and method |
| KR100942880B1 (ko) | 2001-08-29 | 2010-02-17 | 제넨테크, 인크. | 유사분열촉진 활성을 가진 Ｂｖ８ 핵산 및 폴리펩티드 |
| MXPA05009743A (es) | 2003-03-12 | 2006-03-09 | Genentech Inc | Composiciones con actividad hematopoyetica e inmune. |
| RU2386638C2 (ru) | 2004-03-31 | 2010-04-20 | Дженентек, Инк. | Гуманизированные анти-тфр-бета-антитела |
| LT2982372T (lt) | 2005-04-05 | 2020-10-26 | Yale University | Glutamatą moduliuojantys agentai psichikos sutrikimų gydymui |
| WO2007050793A2 (en) | 2005-10-25 | 2007-05-03 | The Johns Hopkins University | Methods and compositions for the treatment of marfan syndrome and associated disorders |
| EP1998810A4 (de) | 2006-03-13 | 2009-09-02 | Univ Johns Hopkins | Erhöhung der endothelialen thromboresistenz |
| PL2918288T3 (pl) | 2006-10-03 | 2018-02-28 | Genzyme Corporation | Zastosowanie antagonistów TGF beta do leczenia niemowląt obarczonych ryzykiem rozwinięcia dysplazji oskrzelowo-płucnej |
| US9089564B2 (en) | 2007-03-22 | 2015-07-28 | The Catholic University of Korea Industry-Academic Cooperatior | Use of EC-SOD for treating angiogenesis-mediated eye diseases |
| JP5581485B2 (ja) | 2007-03-22 | 2014-09-03 | インダストリーアカデミック コーポレーション ファンデーション， ザ カトリックユニバーシティ オブ コリア | Ｅｃ−ｓｏｄの新規な用途及びその製造方法 |
| MX2011001900A (es) | 2008-08-18 | 2011-08-17 | Seoul Nat Univ Ind Foundation | Metodo para controlar metastasis de cancer o migracion de celulas de cancer modulando el nivel celular de lisil-tarn sintetasa. |
| CA2734922C (en) | 2008-09-15 | 2020-01-14 | Genentech, Inc. | Compositions comprising polynucleotides comprising hybrid osmo-responsive transcriptional regulatory elements and methods for producing a protein under conditions of hyperosmolarity |
| KR101102485B1 (ko) | 2008-10-10 | 2012-01-05 | 서울대학교산학협력단 | Ｇｒｓ단백질 또는 이의 단편의 신규한 용도 |
| US8911736B2 (en) | 2010-03-12 | 2014-12-16 | Genzyme Corporation | Combination therapy for treating breast cancer |
| WO2012021249A2 (en) | 2010-07-12 | 2012-02-16 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-trna synthetases |
| KR20130131414A (ko) | 2010-12-27 | 2013-12-03 | 엘에스아이피 환도 운에이고우도우가이샤 | ｉＰＳ 세포와 그 제조법 |
| WO2013014262A1 (en) | 2011-07-27 | 2013-01-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing and treating myhre syndrome |
| CA2853484C (en) | 2011-10-26 | 2018-08-21 | Seattle Children's Research Institute | Cysteamine in the treatment of fibrotic disease |
| EP2751129B1 (de) | 2011-11-23 | 2018-01-24 | Cell Biotech Co., Ltd. | Protein p14 mit krebshemmender sowie antiallergischer wirkung und pharmazeutische zusammensetzung damit |
| ES2917222T3 (es) | 2011-12-28 | 2022-07-07 | Kyoto Prefectural Public Univ Corp | Normalización del cultivo de células endoteliales de la córnea |
| AU2013221317B2 (en) | 2012-02-16 | 2017-07-06 | Pangu Biopharma Limited | Histidyl-tRNA synthetases for treating autoimmune and inflammatory diseases |
| US9493744B2 (en) | 2012-06-20 | 2016-11-15 | Genentech, Inc. | Methods for viral inactivation and other adventitious agents |
| US20130281355A1 (en) | 2012-04-24 | 2013-10-24 | Genentech, Inc. | Cell culture compositions and methods for polypeptide production |
| ES2847383T3 (es) | 2013-03-15 | 2021-08-03 | Atyr Pharma Inc | Conjugados de Fc-histidil-ARNt sintetasa |
| CA2927898C (en) | 2013-10-31 | 2021-11-16 | Kyoto Prefectural Public University Corporation | Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium |
| CA2930687C (en) | 2013-11-15 | 2024-04-23 | Genentech, Inc. | Methods for viral inactivation using eco-friendly detergents |
| KR101619863B1 (ko) | 2014-05-23 | 2016-05-24 | 주식회사 제노포커스 | 신규 베타-갈락토시다아제 |
| KR101730035B1 (ko) | 2015-03-20 | 2017-04-26 | 한국과학기술원 | L-아스파르트산 유도체를 생산하는 변이미생물 및 이를 이용한 l-아스파르트산 유도체의 제조방법 |
| KR101839595B1 (ko) | 2015-04-13 | 2018-04-26 | 한국과학기술원 | 락탐의 제조방법 |
| WO2016187312A1 (en) | 2015-05-18 | 2016-11-24 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods and compositions for treating an alphavirus infection |
| KR20160141123A (ko) | 2015-05-28 | 2016-12-08 | 주식회사 제노포커스 | 고당전이 활성의 베타-갈락토시다제 변이체 및 그 용도 |
| KR101702906B1 (ko) | 2015-07-15 | 2017-02-22 | 주식회사 제노포커스 | 신규 알파-1,3-글루카나제 |
| KR101756338B1 (ko) | 2016-01-15 | 2017-07-10 | 고려대학교 산학협력단 | L-시스테인 생산용 변이미생물 및 이를 이용한 l-시스테인의 제조방법 |
| US9758786B2 (en) | 2016-02-09 | 2017-09-12 | Autotelic, Llc | Compositions and methods for treating pancreatic cancer |
| CA3032512C (en) | 2016-08-02 | 2025-05-06 | Vaccinex, Inc. | IMPROVED PROCESSES FOR PRODUCING POLYNUCLEOTIDE LIBRARIES IN VACCINE VIRUS/EUKARYOTIC CELLS |
| ES2994451T3 (en) | 2017-04-20 | 2025-01-24 | Atyr Pharma Inc | Compositions for treating lung inflammation |
| KR102658830B1 (ko) | 2018-08-02 | 2024-04-19 | 에스케이이노베이션 주식회사 | 내열성 탄산무수화효소 변이체 및 이를 포함하는 이산화탄소 포집용 조성물 |
| KR102346050B1 (ko) | 2019-01-25 | 2022-01-03 | 주식회사 네오믹스 | 미백 활성을 갖는 신규 폴리펩타이드 및 이의 용도 |
| EP4212544A1 (de) | 2020-09-07 | 2023-07-19 | GI Cell, Inc. | Von coronavirus abgeleitete rezeptorbindungsdomänenvariante mit reduzierter ace2-bindungskapazität und impfstoffzusammensetzung damit |
| KR20220059399A (ko) | 2020-11-02 | 2022-05-10 | 한국과학기술원 | 소수성 물질의 생산능이 향상된 재조합 미생물 및 이의 제조를 위한 세포막 엔지니어링 방법 |
| KR102661294B1 (ko) | 2020-12-24 | 2024-04-30 | 한국과학기술원 | 글루타르산 수송체 유전자가 도입된 재조합 미생물 및 이를 이용한 글루타르산의 제조방법 |
| EP4624488A1 (de) | 2022-11-25 | 2025-10-01 | Gil Medical Center | Verwendung des fgf5-transkriptvarianten-2-gens und proteins davon zur prävention, hemmung und behandlung von leberfibrose |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0269408A3 (de) * | 1986-11-26 | 1989-08-30 | Genentech, Inc. | TGF-Beta für die Behandlung von entzündlichen Erkrankungen |
| EP0293785A3 (de) * | 1987-05-29 | 1990-05-02 | Oncogen Limited Partnership | Klonierung und Expression von transformierendem Affenwachstumsfaktor-SS 1 |
| US5221620A (en) * | 1987-10-06 | 1993-06-22 | Oncogen | Cloning and expression of transforming growth factor β2 |
| US5236905A (en) * | 1988-08-25 | 1993-08-17 | Oncogen | In vitro method of inhibition of HIV using transforming growth factor-.beta. |
-
1990
- 1990-10-30 AT AT90917236T patent/ATE131872T1/de not_active IP Right Cessation
- 1990-10-30 JP JP3500456A patent/JPH05503003A/ja active Pending
- 1990-10-30 DE DE69024369T patent/DE69024369T2/de not_active Expired - Fee Related
- 1990-10-30 EP EP90917236A patent/EP0502036B1/de not_active Expired - Lifetime
- 1990-10-30 ES ES90917236T patent/ES2083469T3/es not_active Expired - Lifetime
- 1990-10-30 AU AU67440/90A patent/AU639047B2/en not_active Ceased
- 1990-10-30 DK DK90917236.3T patent/DK0502036T3/da active
- 1990-10-30 CA CA002068204A patent/CA2068204C/en not_active Expired - Fee Related
- 1990-10-30 WO PCT/US1990/006292 patent/WO1991008291A2/en not_active Ceased
-
1996
- 1996-03-19 GR GR960400738T patent/GR3019343T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE69024369T2 (de) | 1996-06-13 |
| ES2083469T3 (es) | 1996-04-16 |
| WO1991008291A2 (en) | 1991-06-13 |
| AU639047B2 (en) | 1993-07-15 |
| GR3019343T3 (en) | 1996-06-30 |
| EP0502036A1 (de) | 1992-09-09 |
| DE69024369D1 (de) | 1996-02-01 |
| CA2068204C (en) | 2002-02-12 |
| JPH05503003A (ja) | 1993-05-27 |
| CA2068204A1 (en) | 1991-05-23 |
| EP0502036B1 (de) | 1995-12-20 |
| AU6744090A (en) | 1991-06-26 |
| DK0502036T3 (da) | 1996-05-06 |
| WO1991008291A3 (en) | 1991-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE131872T1 (de) | Latenz assoziierte peptide und deren verwendung | |
| DE69428214D1 (de) | Transformierender wachstumsfaktor alpha h1 | |
| ZA943464B (en) | Vascular endothelial growth factor 2 | |
| FI901344A0 (fi) | Monoklonala antikroppar reaktiva med tnf. | |
| ATE358176T1 (de) | Menschliche dnase | |
| DK1266965T3 (da) | Rekombinante antistoffer til human terapi | |
| HK102192A (en) | Human tumor necrosis factor and dna therefor | |
| ATE221125T1 (de) | Klonierte glutaminsäure-decarboxylase | |
| ATE321134T1 (de) | Menschlicher fc-gamma-rezeptor iii | |
| EP0670730A4 (de) | Fusionsprotein, das dem rezeptor des tumornekrose-faktors enthält. | |
| PT735818E (pt) | Proteinas inflamatorias de macrofagos pim-3 pim-4 e pim-1y | |
| AU4688589A (en) | A method for treatment of endotoxic shock in a mammal | |
| ATE88900T1 (de) | Konjugate von interferon alpha mit immunglobulinen. | |
| ZA922441B (en) | Glial mitogenic factors,their preparation and use | |
| ATE131493T1 (de) | Polypeptide und polypeptidanaloge mit inhibitorischer aktivität gegenüber menschlicher elastase | |
| DE3875108D1 (de) | Physiologisch aktives polypeptid und pharmazeutische komposition. | |
| EP0810285A3 (de) | Mutanten von menschlichen Interleukin-3 | |
| FI953565A7 (fi) | Uusi antikoagulanttikofaktoriaktiivisuus | |
| DE69024279D1 (de) | Cytokine | |
| EP0348086A3 (en) | Novel peptides, their use as immuno suppressants and processes for their preparation | |
| NO890174L (no) | Rekombinante interleukin-1alfa-polypeptider. | |
| NZ224251A (en) | Synthetic rhinovirus (hrv) peptides and vaccines | |
| KR950701347A (ko) | 신규한 향종양성 사이토킨(A novel anti-neoplastic cytokine) | |
| IT8804860A0 (it) | Procedimento per il recupero di calore, con eventuale recupero od uso dell'umidita', ceduto direttamente o indirettamente dal corpo umano e dispositivo per la sua attuazione. | |
| GR3018675T3 (en) | Antibodies to Promoters of colony stimulating factor activity. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |